HAAO — patent landscape

Top predicted compounds (top 20 by supporting neighbours, then confidence)

Compound	Confidence	Supporting neighbours
SCHEMBL9127844	0.54	1/20
SCHEMBL12168771	0.50	1/20
SCHEMBL20593880	0.50	1/20
SCHEMBL15317983	0.48	1/20
SCHEMBL15317984	0.48	1/20
SCHEMBL128319	0.48	1/20
SCHEMBL31389208	0.48	1/20
SCHEMBL242262	0.47	1/20
SCHEMBL14186130	0.47	1/20
SCHEMBL20850515	0.47	1/20
SCHEMBL28033212	0.47	1/20
SCHEMBL29370019	0.47	1/20
Ammonia Solution, Strong (SCHEMBL29137499)	0.46	1/20
SCHEMBL857301	0.45	1/20
SCHEMBL30083685	0.45	1/20
SCHEMBL680769	0.44	1/20
SCHEMBL257346	0.44	1/20
SCHEMBL317576	0.44	1/20
SCHEMBL489533	0.44	1/20
SCHEMBL2500795	0.44	1/20

Clinical trials — most relevant to HAAO by text similarity (a relevance ranking, not an exhaustive list)

Trial	Phase	Status
Effect of Sevoflurane and Desflurane on Heme Oxygenase-1 Expression in Elective Cholecystectomy	PHASE4	WITHDRAWN
Tryptophan MRI in People With Schizophrenia and Healthy Controls	PHASE2/PHASE3	COMPLETED
Effect of an Isolevuglandin Scavenger on Salt Sensitivity of Blood Pressure and Immune Cell Activation in Humans	PHASE2	NOT_YET_RECRUITING
Multiple N-of-1 Trials of (Intermittent) Hypoxia Therapy in Parkinson's Disease	PHASE1/PHASE2	COMPLETED
A Study With Tasquinimod Treating Patients With Hepatocellular, Ovarian, Renal Cell and Gastric Cancers	PHASE2	COMPLETED
Probenecid (PB) to Treat Hereditary Nephrogenic Diabetes Insipidus (NDI), ADPKD Treated With Tolvaptan, and Severely Polyuric Patients With Previous Lithium Administration	PHASE2	COMPLETED
Effect of Deferoxamine on Wound Healing Rate in Patients With Diabetes Foot Ulcers	PHASE2	NOT_YET_RECRUITING
IDH1 (AG 120) Inhibitor in Patients With IDH1 Mutated Myelodysplastic Syndrome	PHASE2	ACTIVE_NOT_RECRUITING
Diclofenac Dose Response Study	PHASE1	RECRUITING
A Study to Assess the Pharmacokinetics of the Hydrocodone Extended-Release Tablet (CEP-33237) in Subjects With Normal Renal Function and Subjects With Varying Degrees of Renal Impairment	PHASE1	COMPLETED
Nitrite Infusion Studies	PHASE1	COMPLETED
Efavirenz for Patients With Alzheimer's Disease	PHASE1	COMPLETED
Evaluation of the Relationship Between Bruxism and Tryptophan Metabolites	nan	COMPLETED
In Vivo Assessment of Histamine Pharmacodynamics	nan	WITHDRAWN
Vancomycin Associated Red Man Syndrome (RMS)	nan	COMPLETED
Prevalence of DAO (diamino Oxidase) Deficiency in Newborns	nan	COMPLETED
TSK (Tryptophan - Serotonin - Kynurenine) Biomarkers Assessment in Stroke	nan	COMPLETED
Mechanistic Studies of Teriflunomide in RRMS	nan	COMPLETED
Molecular Epidemiology of Dioxin-Related Illness in Seveso	nan	COMPLETED
Lipidomics Screening of Celecoxib in ex Vivo Human Whole Blood Assay - Part B	nan	COMPLETED
Lipidomics Screening of Anti-inflammatory Drugs and Drug Candidates in Vitro - Part A	nan	ACTIVE_NOT_RECRUITING
Genes Associated With Development of Pulmonary Arterial Hypertension in Patients With Congenital Shunt Lesions	nan	RECRUITING
An Assessment of Cognitive Function in Irritable Bowel Syndrome	nan	UNKNOWN
Prevalence and Clinical Effect of IDH1/2 Mutations in Patients With Acute Myeloid Leukemia	nan	UNKNOWN
Oxidative Stress Parameters, Trace Element and Quality of Life in Men Before and After Covid-19 Vaccines	nan	UNKNOWN
Mutation Analysis of 17α-Hydroxylase	nan	UNKNOWN
Involvement of Pollutants in Atopic Dermatitis and Psoriasis	nan	UNKNOWN
Gene-by-Smoking Interactions and Risk of Atherosclerosis - Ancillary to ARIC	nan	COMPLETED
Relation Between Prostaglandin E2 Metabolite Levels and the Development of Hemodynamically Significant Patent Ductus Arteriosus in Preterm Neonates	nan	RECRUITING
EPICO: (Study for the Pro-resolution of Chronic Inflammation in Obesity. Original Acronym From Spanish)	nan	UNKNOWN

Related proteins — ESM-2 sequence neighbours (a HAAO binder may also engage these)

Protein	Name	Similarity
P46953	—	1.000	P46953 →
Q0VCA8	—	1.000	Q0VCA8 →
Q78JT3	—	1.000	Q78JT3 →
Q5U3F8	—	0.985	Q5U3F8 →
Q6DIZ0	—	0.984	Q6DIZ0 →
Q6P7I0	—	0.980	Q6P7I0 →
Q5ZL43	—	0.969	Q5ZL43 →
Q99JT9	—	0.967	Q99JT9 →
A7RIT9	—	0.967	A7RIT9 →
RIOX2	Ribosomal oxygenase 2	0.967	landscape →
Q5EA24	—	0.967	Q5EA24 →
Q9BV57	—	0.967	Q9BV57 →
Q3ZBL1	—	0.966	Q3ZBL1 →
O48707	—	0.964	O48707 →
Q5R673	—	0.963	Q5R673 →
F6QS54	—	0.963	F6QS54 →
C5WWY0	—	0.962	C5WWY0 →
Q8GXE2	—	0.962	Q8GXE2 →
F6HDT7	—	0.962	F6HDT7 →
Q8W108	—	0.962	Q8W108 →
Q8BML9	—	0.961	Q8BML9 →
Q562C9	—	0.961	Q562C9 →
A2Z7C4	—	0.961	A2Z7C4 →
A1L4T4	—	0.961	A1L4T4 →
F7FKV1	—	0.960	F7FKV1 →
C5X1F5	—	0.960	C5X1F5 →
B4T512	—	0.959	B4T512 →
B4TGS4	—	0.959	B4TGS4 →
Q9ZEU6	—	0.959	Q9ZEU6 →
Q8ZM98	—	0.958	Q8ZM98 →